Department of Endocrinology & Metabolism, Academic Medical Center, University of Amsterdam, The Netherlands.
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):359-70. doi: 10.1016/j.beem.2011.11.001.
General health-related quality-of-life (QoL) questionnaires (MOS SF-24 and SF-36) and the more sensitive disease-specific QoL questionnaire (GO-QoL) both indicate substantial impairment of quality of life in patients with Graves' ophthalmopathy (GO). The GO-QoL contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best). The minimal clinically important difference in scores is ≥10 points for invasive therapies, but a change of 6 points on one of both subscales is already perceived by patients as beneficial and associated with an important change in daily functioning. The GO-QoL is well validated, widely used, and available in eight languages. The GO-QoL is recommended as an independent primary outcome measure in randomized clinical trials. Incorporating the GO-QoL in the routine assessment of GO in daily clinical practice is also recommended: although unproven, it is likely to improve the quality of care by identifying patients who are in need for psychological support in order to address poor psychosocial functioning and low self-esteem.
一般健康相关的生活质量（QoL）问卷（MOS SF-24 和 SF-36）和更敏感的疾病特异性 QoL 问卷（GO-QoL）都表明格雷夫斯眼病（GO）患者的生活质量受到严重损害。GO-QoL 包含 8 个关于视觉功能的问题和 8 个关于外观的问题；每个子量表的答案都转换为 0（最差）到 100（最好）的分数。对于侵袭性治疗，评分的最小临床重要差异≥10 分，但两个子量表之一的 6 分变化已被患者认为是有益的，并与日常功能的重要变化相关。GO-QoL 经过良好验证，应用广泛，有八种语言版本。GO-QoL 被推荐为随机临床试验中的独立主要结局指标。在日常临床实践中，将 GO-QoL 纳入 GO 的常规评估也被推荐：虽然未经证实，但它可能通过识别需要心理支持以解决不良社会心理功能和低自尊的患者来提高护理质量。
